Selective serotonin reuptake inhibitor discontinuation with ECT and withdrawal symptoms.
Markowitz
J S
JS
D015057:1-Naphthylamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000175:diagnosis / Q000628:therapy*; D003937:Diagnosis, Differential; D004565:Electroconvulsive Therapy; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D020280:Sertraline; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis / Q000209:etiology*
D015057:1-Naphthylamine; D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline